Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children
- PMID: 12607791
- DOI: 10.1097/00005176-200211004-00003
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children
Abstract
Objectives: To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age. In addition, the efficacy in healing of erosive esophagitis (EE) was determined in those children with EE who were enrolled in the study.
Methods: In this phase I/II, open-label, multicenter (11 sites) U.S. study, children with symptomatic GERD, EE by endoscopy, and/or intraesophageal pH < 4 for greater than 4.2% of the time based on 24-hour pH testing were assigned, on the basis of body weight, to lansoprazole 15 mg (< or = 30 kg) or 30 mg (> 30 kg) once daily for 8 to 12 weeks. At the discretion of the investigator, the dosage of lansoprazole was increased up to 60 mg daily in children who continued to be symptomatic after 2 weeks of treatment. Symptom response was assessed by investigator interview and daily diary. Esophagitis healing was evaluated by repeat endoscopy after 8 and, if applicable, 12 weeks of treatment.
Results: Sixty-six children were enrolled. At week 8, 78% (21/27) of the children with EE at baseline had healed; the remaining six children were healed by week 12 (100%, 6/6). By investigator interview, 70% of children experienced resolution or improvement in their overall symptoms of GERD by their final visit. Statistically significant reductions from baseline in the severity of each symptom were reported with the exceptions of wheezing, hematemesis, and melena. Based on daily diary data, improvement in overall GERD symptoms was reported in 76% (47/62) of all children. With few exceptions, significant (P < 0.05) reductions from baseline occurred during each of the 2-week treatment intervals of the study period in the percentage of days and the average daily severity of GERD symptoms, the percentage of days antacid was used, and the average number of antacid tablets used per day.
Conclusion: In children 1 to 11 years of age, lansoprazole is efficacious in healing EE and in relieving GERD-related symptoms.
Similar articles
-
Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.J Pediatr Gastroenterol Nutr. 2002;35 Suppl 4:S300-7. doi: 10.1097/00005176-200211004-00002. J Pediatr Gastroenterol Nutr. 2002. PMID: 12607790 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.J Pediatr Gastroenterol Nutr. 2007 Jan;44(1):35-40. doi: 10.1097/01.mpg.0000242556.57434.2e. J Pediatr Gastroenterol Nutr. 2007. PMID: 17204950 Clinical Trial.
-
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.J Pediatr Gastroenterol Nutr. 2005 Mar;40(3):319-27. doi: 10.1097/01.mpg.0000155369.54464.41. J Pediatr Gastroenterol Nutr. 2005. PMID: 15735486 Clinical Trial.
-
Lansoprazole: in the management of gastroesophageal reflux disease in children.Paediatr Drugs. 2003;5(1):57-61; discussion 62. doi: 10.2165/00128072-200305010-00005. Paediatr Drugs. 2003. PMID: 12513106 Review.
-
Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.Drugs. 2005;65(15):2129-35; discussion 2136-7. doi: 10.2165/00003495-200565150-00005. Drugs. 2005. PMID: 16225368 Review.
Cited by
-
Prevalence of Non-erosive Esophageal Phenotypes in Children: A European Multicenter Study.J Neurogastroenterol Motil. 2023 Apr 30;29(2):156-165. doi: 10.5056/jnm22115. J Neurogastroenterol Motil. 2023. PMID: 37019861 Free PMC article.
-
Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children.Clin Drug Investig. 2005;25(5):285-92. doi: 10.2165/00044011-200525050-00001. Clin Drug Investig. 2005. PMID: 17532666
-
Long-term use of PPIs in children: we have questions.Dig Dis Sci. 2008 Apr;53(4):1158-60, author reply 1161-2. doi: 10.1007/s10620-008-0213-2. Epub 2008 Feb 8. Dig Dis Sci. 2008. PMID: 18259863 No abstract available.
-
Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5-11 years.Paediatr Drugs. 2004;6(2):127-31. doi: 10.2165/00148581-200406020-00006. Paediatr Drugs. 2004. PMID: 15035653
-
Long-term proton pump inhibitor use in children: a retrospective review of safety.Dig Dis Sci. 2008 Feb;53(2):385-93. doi: 10.1007/s10620-007-9880-7. Epub 2007 Aug 4. Dig Dis Sci. 2008. PMID: 17676398
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical